Clear, trusted answers about Ebola — when it matters most
Ebola virus disease is one of the world's most dangerous infectious diseases. This resource compiles peer-reviewed research, expert guidance, and verified reporting to help you understand the virus's biology, transmission, outbreaks, vaccines, and treatment.
Current reporting and updates on Ebola virus disease from verified news sources. Updated daily. View archived news →
Last updated: May 21, 2026
The World Health Organization declared a Public Health Emergency of International Concern on May 17, 2026 following the identification of a novel Ebola variant in Ituri Province, Democratic Republic of the Congo. The variant does not match any previously known strain and no licensed vaccine is currently available.
Source: WHO
The Democratic Republic of the Congo declared a new Ebola outbreak on May 15, 2026 in the health zones of Bunia, Mongwalu, and Rwampara in Ituri Province. Health authorities confirmed the causative agent is a newly identified Ebola variant that does not match any previously characterized strain.
Source: CDC
Researchers at the Institut National de Recherche Biomédicale and international partners are urgently testing whether FDA-approved treatments Inmazeb and Ebanga retain efficacy against the novel Ebola variant identified in Ituri Province. Early genomic sequencing suggests significant divergence from the Zaire ebolavirus strain the treatments were designed for.
Source: STAT News
The U.S. Centers for Disease Control and Prevention raised its travel advisory for Ituri Province, DRC to Level 3 — Avoid Nonessential Travel — as the novel Ebola outbreak expanded to three health zones. Airport entry screening has been activated for travelers arriving from affected regions.
Source: CDC
Merck and Janssen, manufacturers of the approved Ervebo and Zabdeno/Mvabea Ebola vaccines respectively, announced emergency scientific assessments to determine whether existing vaccine platforms can be adapted to protect against the novel Ituri Province variant. WHO is coordinating the global scientific response.
Source: WHO
Médecins Sans Frontières (Doctors Without Borders) deployed emergency response teams to Bunia, Ituri Province, as the novel Ebola outbreak strained local healthcare capacity. MSF reported that contact tracing efforts are ongoing and an Ebola Treatment Unit is being established.
Source: NPR Health
Advertisement
Ebola outbreaks are declared by national health ministries and the WHO. This section tracks active and recent outbreaks. Always verify with WHO Disease Outbreak News for the latest official status.
Sources: WHO Disease Outbreak News, CDC Ebola
Ebola virus disease progresses in two clinical phases. Early recognition of symptoms is critical for isolation, treatment, and preventing spread.
Symptoms typically begin 8–10 days after exposure (range: 2–21 days). The incubation period is not infectious — a person can only spread Ebola once symptoms begin.
As the disease progresses, systemic symptoms develop. This phase is highly contagious due to virus-laden body fluids.
Yes. Early Ebola symptoms are similar to malaria, typhoid, cholera, and other viral hemorrhagic fevers. In regions where Ebola is circulating, healthcare providers use travel history, exposure history, and laboratory testing to distinguish Ebola from these conditions. PCR blood testing is the definitive diagnostic method.
In fatal cases, death typically occurs between days 6 and 16 of symptoms, usually from multiple organ failure, severe fluid loss, and uncontrolled bleeding. Survivors may experience weeks of recovery and can have lasting effects including fatigue, musculoskeletal pain, and eye problems. The virus can persist in certain body fluids (including semen) for months after recovery.
Case fatality rates vary significantly by strain and access to care. Zaire ebolavirus (the most common outbreak strain) has historically killed 60–90% of infected people without treatment. With modern supportive care and the antiviral treatments mAb114 and REGN-EB3, survival rates have improved substantially. Bundibugyo ebolavirus has a lower fatality rate of approximately 25–50%. The fatality rate for the novel 2026 DRC variant is not yet established.
Understanding Ebola transmission is essential for prevention. Unlike influenza or COVID-19, Ebola does not spread through the air — it requires direct contact with infectious body fluids.
The natural reservoir of Ebola virus is believed to be fruit bats, particularly in the family Pteropodidae. The virus appears to circulate in bat populations without causing disease in the bats themselves. Human outbreaks typically begin when a person comes into contact with an infected animal — either a bat directly or an intermediate host such as non-human primates (gorillas, chimpanzees). Once in a human, the virus spreads person-to-person through direct contact.
Yes, in limited ways. While Ebola survivors are no longer contagious through casual contact once they have recovered, the virus can persist in certain "immune-privileged" sites — most notably semen — for extended periods. Viral RNA has been detected in semen up to 500 days after symptom onset in some cases. The WHO recommends that male survivors use condoms or abstain from sex for at least 12 months, or until their semen tests negative twice.
Advertisement
Treatment for Ebola has advanced significantly since the 2014–16 epidemic. Two FDA-approved antiviral treatments now exist, and vaccines are available for some strains — though not for the novel 2026 DRC variant.
Supportive care remains the foundation of Ebola treatment and significantly improves survival:
Early initiation of supportive care is strongly associated with improved survival outcomes.
Approved: FDA approval October 2020 — first FDA-approved treatment for Ebola.
How it works: A cocktail of three monoclonal antibodies (atoltivimab, maftivimab, odesivimab) that bind to the Ebola virus glycoprotein and prevent cell entry.
Evidence: The PALM trial demonstrated a 29-day mortality of 33.5% with REGN-EB3 vs. 51% with ZMapp control in Zaire ebolavirus patients.[T1]
Limitation: Approved for Zaire ebolavirus only. Efficacy against the novel 2026 variant is unknown.
Approved: FDA approval December 2020.
How it works: A single monoclonal antibody derived from a survivor of the 1995 DRC Ebola outbreak. Targets the receptor-binding domain of the Ebola glycoprotein.
Evidence: The same PALM trial showed 29-day mortality of 35.1% with mAb114 — comparable to REGN-EB3 and superior to ZMapp.[T1]
Limitation: Approved for Zaire ebolavirus only.
Approved: FDA approval December 2019; WHO prequalification 2019.
How it works: A live attenuated recombinant vesicular stomatitis virus (rVSV) engineered to express the Zaire ebolavirus glycoprotein.
Efficacy: The Guinea Ring Vaccination Trial showed 100% efficacy (95% CI: 63.5–100%) with no cases in vaccinated contacts vs. 23 cases in controls.[T2]
Use: Recommended by WHO for outbreak response in adults. Used in ring vaccination campaigns in DRC and Guinea outbreaks.
⚠️ Not effective against the novel 2026 DRC variant.
Approved: European Medicines Agency (EMA) approval July 2020.
How it works: A two-dose prime-boost regimen. Zabdeno (Ad26.ZEBOV) uses an adenovirus vector expressing Zaire ebolavirus glycoprotein; Mvabea (MVA-BN-Filo) is a Modified Vaccinia Ankara vector expressing multiple filovirus antigens.
Use: Designed for pre-emptive vaccination in at-risk populations before outbreaks. The two doses are given 56 days apart, making it less practical for rapid outbreak response than Ervebo.
⚠️ Not approved for the novel 2026 DRC variant.
Disclosure: As an Amazon Associate, EbolaQuestions.com earns from qualifying purchases. These recommendations are for general preparedness and informational purposes, not medical advice. Always follow institutional and public health protocols.
NIOSH-approved N95 respirators provide the highest filtration efficiency (≥95%) for healthcare workers in infectious disease settings. While Ebola is not airborne, respiratory protection is part of full PPE protocol for patient care.
Shop N95/KN95 Masks on Amazon →Double-gloving with nitrile gloves is standard in Ebola patient care settings. Heavy-duty nitrile provides superior chemical and puncture resistance compared to latex for high-risk contact.
Shop Nitrile Gloves on Amazon →Fever screening at ports of entry, hospitals, and community checkpoints is a key outbreak control measure. Contactless infrared thermometers allow rapid temperature screening without physical contact.
Shop Contactless Thermometers on Amazon →Fluid-resistant or impermeable isolation gowns are essential PPE for healthcare workers in Ebola treatment units. ANSI/AAMI Level 4 gowns provide the highest protection level for high-splash-risk procedures.
Shop Isolation Gowns on Amazon →Ebola was first identified in 1976. Since then, there have been dozens of outbreaks, primarily in sub-Saharan Africa. The 2014–16 West Africa epidemic was by far the largest.
Two simultaneous outbreaks occurred in 1976: one in Nzara, Sudan (now South Sudan), caused by Sudan ebolavirus (284 cases, 151 deaths), and one near the Ebola River in Yambuku, DRC (then Zaire), caused by Zaire ebolavirus (318 cases, 280 deaths). The virus was named after the Ebola River.
A major outbreak of Zaire ebolavirus in Kikwit, DRC resulted in 315 cases and 254 deaths (81% case fatality rate). The outbreak highlighted the role of hospital amplification and inadequate infection control in spreading Ebola.
An outbreak of Sudan ebolavirus in Gulu, Uganda resulted in 425 cases and 224 deaths — the largest Sudan ebolavirus outbreak ever recorded.
The deadliest Ebola outbreak in history spread across Guinea, Liberia, and Sierra Leone, with isolated cases reaching Nigeria, Mali, Senegal, the U.S., UK, Spain, and Italy. Final toll: approximately 28,616 cases and 11,310 deaths. The outbreak devastated healthcare systems, orphaned thousands of children, and triggered the accelerated development of the Ervebo vaccine.[H1]
The second-largest Ebola outbreak in history: 3,481 cases and 2,299 deaths in eastern DRC. The response was severely complicated by active armed conflict and community mistrust. The Ervebo vaccine was deployed for the first time in an active outbreak setting and is credited with preventing a far larger epidemic.
An outbreak of Sudan ebolavirus in Uganda (164 confirmed cases, 77 deaths) was particularly alarming because no licensed vaccine existed for Sudan ebolavirus — Ervebo only protects against Zaire ebolavirus. Experimental Sudan vaccines were deployed under compassionate use. The outbreak was declared over January 11, 2023.
Declared May 15, 2026 in Ituri Province. The outbreak involves a newly identified Ebola variant that does not match any previously known strain, meaning existing vaccines and antivirals have unconfirmed efficacy. A WHO Public Health Emergency of International Concern was declared May 17, 2026. Investigation ongoing.
Advertisement
Healthcare workers (HCWs) are at the highest risk of Ebola infection. This section covers PPE protocols, isolation procedures, and reporting requirements.
Full Ebola PPE (per CDC/WHO guidance) includes:
Trained donning and doffing procedures are critical — a significant proportion of HCW infections occur during PPE removal.
Confirmed or suspected Ebola patients must be placed in:
All healthcare facilities should have a written Ebola response plan and a designated Ebola response team.
In the United States, Ebola is a nationally notifiable disease. Healthcare providers must:
For suspected Ebola in a patient with compatible symptoms and epidemiologic risk:
Ebola outbreaks are geographically concentrated. Understanding current travel advisories is essential for anyone traveling to or from affected regions.
The CDC has issued a Level 3: Avoid Nonessential Travel advisory for Ituri Province, DRC due to the active Ebola outbreak. Travelers are advised to:
Disclosure: The following links are affiliate links. EbolaQuestions.com may earn a commission on purchases at no additional cost to you. We recommend only providers with strong emergency medical evacuation coverage for infectious disease events.
Standard travel insurance often excludes epidemic/outbreak events. Look for policies that specifically cover emergency medical evacuation, infectious disease hospitalization, and trip cancellation due to declared public health emergencies.
Compare Travel Insurance Options →WHO-recommended hand hygiene formulations (70% isopropyl or 80% ethanol) are effective against Ebola virus. Travel-size sanitizers are essential when soap and water are unavailable.
Shop Hand Sanitizer on Amazon →Ebola outbreaks consistently generate dangerous misinformation that undermines outbreak response, discourages people from seeking care, and fuels community distrust. Here is the evidence behind the most common false claims.
The claim: Ebola can be transmitted by breathing the same air as an infected person.
The evidence: Ebola is not transmitted via the airborne route under normal conditions. The CDC, WHO, and all major infectious disease organizations are unequivocal on this point. Transmission requires direct contact with infected body fluids. This misconception causes unnecessary panic and discriminatory treatment of people from affected regions.
The claim: Pharmaceutical companies or governments possess a cure for Ebola but are withholding it for financial or political reasons.
The evidence: Two FDA-approved monoclonal antibody treatments (Inmazeb and Ebanga) were developed following the 2014–16 epidemic and are used in current outbreak responses. These were made available through humanitarian programs. Research continues. The challenge is manufacturing capacity and distribution in remote, conflict-affected regions — not secrecy.
The claim: Ebola vaccines are a Western conspiracy to reduce African populations or conduct medical experiments.
The evidence: This is a harmful conspiracy theory without factual basis. The Ervebo vaccine was developed in collaboration with African scientists and governments, underwent rigorous clinical trials including major trials conducted in Guinea and DRC with full informed consent, and was found safe and highly effective. Vaccine hesitancy fueled by this misinformation cost lives during the 2018–20 DRC outbreak.
The claim: Sending an Ebola patient to a hospital or Ebola treatment unit (ETU) is a death sentence; they should be treated at home.
The evidence: This belief, common in some affected communities during the 2014–16 epidemic, was tragically counterproductive. Early treatment at ETUs significantly improves survival odds through supportive care, antivirals, and expert monitoring. Home care of Ebola patients dramatically increases transmission risk to family members and is a primary driver of community spread.
The claim: Various traditional medicines, plant remedies, or ritual practices can treat or prevent Ebola.
The evidence: No traditional remedy has demonstrated efficacy against Ebola in clinical evidence. Reliance on these remedies delays patients from accessing effective care, worsening outcomes and increasing transmission. Traditional healers who treat patients without protective equipment are at very high risk of infection and have been sources of outbreak amplification in past epidemics.
Ebola has been the subject of intensive research since 1976, dramatically accelerating after the 2014–16 epidemic. Below are landmark studies and authoritative resources spanning virology, treatment, vaccines, and epidemiology.
Last updated: May 21, 2026
New England Journal of Medicine
The Lancet Infectious Diseases
JAMA
Nature Medicine
Clinical Infectious Diseases